No Data
No Data
China Resources Boya Bio-Pharmaceutical Group (300294.SZ) had 17,587 shareholders, including those with margin trading accounts, on June 28th.
On June 28, 2024, there were 17,587 shareholders of China Resources Boya Bio-pharmaceutical Group (300294.SZ) on the investor interaction platform, including those with credit accounts.
Is China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
China Resources Boya Bio-pharmaceutical Group (300294.SZ): No business cooperation with Dirui Industrial.
China Resources Boya Bio-Pharmaceutical Group (300294.SZ) stated on the investor interactive platform on June 25th that the company has no business cooperation with Dirui Industrial.
Huaxin Securities: Both the supply and demand sides of blood products continue to improve, and the scale effect of leading companies gradually emerges.
According to the research reports released by Huaxin Securities, with the support and attention of domestic policies, the planning of new plasma stations such as the "14th Five-Year Plan" will gradually be implemented, and the construction of plasma stations will accelerate. China's plasma collection scale will continue to increase. In 2023, the plasma collection volume will exceed 12079 tons, an increase of more than 18.6% compared with 2022. Blood products belong to essential pharmaceuticals, and the entire industry is a licensed business, which determines its natural high policy barrier characteristics. The scale of plasma collection, the comprehensive utilization rate of blood plasma, and the profit-making ability of blood plasma are the core factors. The scale of plasma collection directly determines the scale of the enterprise. The number of existing varieties and research products are used to determine the comprehensive utilization rate and profit-making ability of blood plasma.
Morgan Stanley Starts China Resources Boya Bio-pharmaceutical Group at Equal-weight; Price Target Is 37 Yuan
12:13 AM EDT, 05/27/2024 (MT Newswires) -- Morgan Stanley Starts China Resources Boya Bio-pharmaceutical Group at Equal-weight; Price Target is 37 Yuan Price (RMB): ¥32.46, Change: ¥-0.15, Percent Cha
Liberal Arts Biotech (300294.SZ): On May 20, 2024, the number of shareholders was 18,115
Gelonghui, May 21丨Liberal Arts Biotech (300294.SZ) said on the investor interactive platform that the number of shareholders in the company's consolidated register including credit accounts was 18,115 on May 20, 2024.
No Data